Regeneron Pharmaceuticals Inc at Wells Fargo Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Mohit Bansal - Wells Fargo & Co - Analyst : Great. So I mean in terms of -- I mean like so obviously, there was a period of time then when fasinumab was on the market and you, obviously you -- it's always some pressure on incumbent because of that. So there was some gradual decline in market share. So I mean at this point, how do you think about EYLEA plus high-dose EYLEA as category? In terms of the category, do they keep the market share? Or do you expect that to grow market share as well?

Question: Mohit Bansal - Wells Fargo & Co - Analyst : Got it. No, that makes sense. And then -- so I think you mentioned 20% of switches last quarter came from the fasinumab. So do you -- could you give us some sense why these patients are switching? . REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 05, 2024 / 4:45PM, REGN.OQ - Regeneron Pharmaceuticals Inc at Wells Fargo Healthcare Conference

Question: Mohit Bansal - Wells Fargo & Co - Analyst : Got it. That makes sense. And then there are some questions we get on the overall market growth for VEGF market. So I mean there's obviously VEGF market and there's branded VEGF market. You mentioned that you're getting some share from (inaudible). So can you talk a little bit about the overall VEGF market as well as branded market? In the past, there were times when it was really high single digit, 8%, 9%. But again, I mean, how do any cannot forecast that. But -- how -- what are you seeing right now? Has the trend slowed down a little bit? Or do you see a similar level of growth that you saw in the past year? .

Question: Mohit Bansal - Wells Fargo & Co - Analyst : Got it. That completely makes sense. And then also from the EYLEA HD point of view, in the real world, what dosing interests, probably like now one year, like what kind of dosing interims you are changing in the real world? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 05, 2024 / 4:45PM, REGN.OQ - Regeneron Pharmaceuticals Inc at Wells Fargo Healthcare Conference

Question: Mohit Bansal - Wells Fargo & Co - Analyst : Got it. And then -- so I mean, overall, when you have -- so in the last one year, the pace of conversion versus your initial expectations, where would you rank it? Like you think it is in line with expectations? Or do you think it is going better than expectation?

Question: Mohit Bansal - Wells Fargo & Co - Analyst : One last question on this, I promise.

Question: Mohit Bansal - Wells Fargo & Co - Analyst : Actually. In terms of prefilled syringe, where do you stand? And I mean what are the timelines there? . REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 05, 2024 / 4:45PM, REGN.OQ - Regeneron Pharmaceuticals Inc at Wells Fargo Healthcare Conference

Question: Mohit Bansal - Wells Fargo & Co - Analyst : Awesome. On that high note, we'll just switch gears to other small product, you have called DUPIXENT. So I mean I think maybe let's just talk about AD first, atopic dermatitis first, before we move into COPD. So I mean, like obviously, like this is a question we get -- we ask every year like now you have done so well in atopic dermatitis, like, where would the growth come from? How much more market expansion opportunity there is? And can you talk a little bit about that?

Question: Mohit Bansal - Wells Fargo & Co - Analyst : Awesome. No, this is remarkable. In terms of -- there is some competition coming down the line with obviously lebrikizumab is coming and then there are some OX-40s as well. So how do you -- sort of when you talk to physicians, how do you see these as competition?

Question: Mohit Bansal - Wells Fargo & Co - Analyst : How strong an argument this monthly goes increase from IL-13?

Question: Mohit Bansal - Wells Fargo & Co - Analyst : Got it. This is very helpful. So maybe moving on to COPD. So maybe if there is a manufacturing update or any update you have at this point?

Question: Mohit Bansal - Wells Fargo & Co - Analyst : No, this is -- I think I crossed that [limbo]. That's why I asked (inaudible), but regulatory update. But thank you for that. So no, in terms of commercial, I mean like -- because you are already in asthma. So you're probably going to clinics already. So how much does it help with the commercial part when you have the product already in the same clinics?

Question: Mohit Bansal - Wells Fargo & Co - Analyst : Awesome. No, this is very helpful. I mean I think one question I want to ask you, Ryan. I mean, what -- is there a time line to think about when could we see the CMA plus DUPIXENT data analysis?

Question: Mohit Bansal - Wells Fargo & Co - Analyst : And we could see [optional] food challenge data later this year?

Question: Mohit Bansal - Wells Fargo & Co - Analyst : Got it. No, this is super helpful. Maybe like again, oncology is another area where, given LIBTAYO, you are behind the leaders. Initially, people did not give you a lot of credit, but again, LIBTAYO is doing well now. So I mean it's a blockbuster product, and then you have other stuff coming. So how do you -- like when you look at that portfolio, how do you think about the portfolio and growth? And then for Opdualag -- sorry for (inaudible), combination, how important it is to have [beta data] versus Opdualag versus (inaudible)?

Question: Mohit Bansal - Wells Fargo & Co - Analyst : Great. So I mean, in the last few minutes, two key pipeline assets, which we get a lot of questions on. I think -- so I want to talk about IL-33 as well in COPD next year. How should we think about that asset? And what is your confidence level in terms of data in the next year?

Question: Mohit Bansal - Wells Fargo & Co - Analyst : Got it. And then since you are not including current smoker, then which is the patient at this point, right? .

Question: Mohit Bansal - Wells Fargo & Co - Analyst : Got it. And then the other one, is definitely myostatin, which we hear a lot about. So I mean, what are your current thoughts there? And then I think I do want to ask about the dosage, the doses -- the dose is pretty big there. So I mean, like how are you thinking about -- obviously, we'll have data next year probably, right? So are you thinking about long-term development plan?

Question: Mohit Bansal - Wells Fargo & Co - Analyst : Awesome. So one last question. Fast forward one year, 2025 September. I hope you are here. So what would make you look back at this year and then as that year pass and you say it is a great year for us.

Question: Mohit Bansal - Wells Fargo & Co - Analyst : Maybe you release some of the data on the morning of --?

Question: Mohit Bansal - Wells Fargo & Co - Analyst : Awesome. On that high note, thank you very much for joining us.